This Article Full Text Full Text (PDF) All Versions of this Article: 106/6/740    most recent 01.CIR.0000023942.10849.41v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zhang, Z. Articles by Chopp, M. Search for Related Content PubMed PubMed Citation Articles by Zhang, Z. Articles by Chopp, M. Related Collections Embolic stroke Other imaging Thrombolysis

(Circulation. 2002;106:740.)
© 2002 American Heart Association, Inc.

Basic Science Reports

Adjuvant Treatment With Neuroserpin Increases the Therapeutic Window for Tissue-Type Plasminogen Activator Administration in a Rat Model of Embolic Stroke

Zhenggang Zhang, MD, PhD; Li Zhang, MD; Manuel Yepes, MD; Quan Jiang, PhD; Qingjiang Li, BS; Polly Arniego, MS; Timothy A. Coleman, PhD; Daniel A. Lawrence, PhD; Michael Chopp, PhD

From the Department of Neurology (Z.Z., L.Z., Q.J., Q.L. P.A., M.C.), Henry Ford Health Sciences Center, Detroit, Mich; Department of Vascular Biology (M.Y., D.A.L.), J.H. Holland Laboratory, American Red Cross, Rockville, Md; Department of Neurology (M.Y.), Georgetown University Medical Center, Washington, DC; Department of Protein Development (T.A.C.), Human Genome Sciences Inc, Rockville, Md; and Department of Physics (M.C.), Oakland University, Rochester, Mich.

Correspondence to Michael Chopp, PhD, Henry Ford Hospital, Department of Neurology, 2799 West Grand Blvd, Detroit, MI 48202. E-mail chopp{at}neuro.hfh.edu

Background— After stroke, the thrombolytic effect of tissue-type plasminogen activator (tPA) in the intravascular space is beneficial, whereas its extravascular effect on ischemic neurons is deleterious. We tested the hypothesis that neuroserpin, a natural inhibitor of tPA, reduces tPA-induced neuronal toxicity and increases its therapeutic window for treatment of embolic stroke.

Methods and Results— Rats were subjected to embolic middle cerebral artery occlusion (MCAO). Ischemic brains were treated with neuroserpin in combination with recombinant human tPA (n=7), tPA alone (n=7), or saline (n=9). Neuroserpin (20 µL of 16 µmol/L active neuroserpin) was intracisternally injected 3 hours and tPA (10 mg/kg) was intravenously administered 4 hours after ischemia. MRI measurements were performed to study blood brain barrier (BBB) leakage and ischemic lesion volume. Administration of tPA alone 4 hours after ischemia significantly (P<0.05) increased BBB leakage in the ischemic core measured by Gd-DTPA–enhanced MRI compared with rats treated with saline. However, treatment with neuroserpin in combination with tPA significantly (P<0.05) reduced BBB leakage, brain edema, and ischemic lesion volume compared with rats treated with tPA alone, although ischemic lesion volumes were the same in both groups before the treatment. Immunostaining revealed that MCAO resulted in reduction of neuroserpin immunoreactivity in the ipsilateral hemisphere after 2 to 6 hours of ischemia. Zymographic assay showed increased plasminogen activity in areas with BBB leakage in rats treated with tPA.

Conclusions— Administration of neuroserpin after stroke is neuroprotective, seemingly because it blocks the extravascular effect of tPA, leading to subsequent decrease in stroke volume and widening of the therapeutic window for the thrombolytic effect of tPA.

Key Words: stroke • plasminogen activators • magnetic resonance imaging • thrombolysis

This article has been cited by other articles:

				A. L. Samson, R. J. Borg, B. Niego, C. H. Y. Wong, P. J. Crack, T. Yongqing, and R. L. Medcalf A nonfibrin macromolecular cofactor for tPA-mediated plasmin generation following cellular injury Blood, August 27, 2009; 114(9): 1937 - 1946. [Abstract] [Full Text] [PDF]

				N. Lebeurrier, S. Launay, R. Macrez, E. Maubert, H. Legros, A. Leclerc, S. P. Jamin, J.-Y. Picard, S. Marret, V. Laudenbach, et al. Anti-Mullerian-hormone-dependent regulation of the brain serine-protease inhibitor neuroserpin J. Cell Sci., October 15, 2008; 121(20): 3357 - 3365. [Abstract] [Full Text] [PDF]

				J. An, C. Zhang, R. Polavarapu, X. Zhang, X. Zhang, and M. Yepes Tissue-type plasminogen activator and the low-density lipoprotein receptor-related protein induce Akt phosphorylation in the ischemic brain Blood, October 1, 2008; 112(7): 2787 - 2794. [Abstract] [Full Text] [PDF]

				K. Danielyan, K. Ganguly, B.-S. Ding, D. Atochin, S. Zaitsev, J.-C. Murciano, P. L. Huang, S. E. Kasner, D. B. Cines, and V. R. Muzykantov Cerebrovascular Thromboprophylaxis in Mice by Erythrocyte-Coupled Tissue-Type Plasminogen Activator Circulation, September 30, 2008; 118(14): 1442 - 1449. [Abstract] [Full Text] [PDF]

				E. E. Benarroch Tissue plasminogen activator: Beyond thrombolysis Neurology, August 21, 2007; 69(8): 799 - 802. [Full Text] [PDF]

				D. Strbian, M.-L. Karjalainen-Lindsberg, P. T. Kovanen, T. Tatlisumak, and P. J. Lindsberg Mast Cell Stabilization Reduces Hemorrhage Formation and Mortality After Administration of Thrombolytics in Experimental Ischemic Stroke Circulation, July 24, 2007; 116(4): 411 - 418. [Abstract] [Full Text] [PDF]

				E. Dai, K. Viswanathan, Y. M. Sun, X. Li, L. Y. Liu, B. Togonu-Bickersteth, J. Richardson, C. Macaulay, P. Nash, P. Turner, et al. Identification of Myxomaviral Serpin Reactive Site Loop Sequences That Regulate Innate Immune Responses J. Biol. Chem., March 24, 2006; 281(12): 8041 - 8050. [Abstract] [Full Text] [PDF]

				L. Zhang, Z. G. Zhang, G. L. Ding, Q. Jiang, X. Liu, H. Meng, A. Hozeska, C. Zhang, L. Li, D. Morris, et al. Multitargeted Effects of Statin-Enhanced Thrombolytic Therapy for Stroke With Recombinant Human Tissue-Type Plasminogen Activator in the Rat Circulation, November 29, 2005; 112(22): 3486 - 3494. [Abstract] [Full Text] [PDF]

				K. Benchenane, V. Berezowski, C. Ali, M. Fernandez-Monreal, J. P. Lopez-Atalaya, J. Brillault, J. Chuquet, A. Nouvelot, E. T. MacKenzie, G. Bu, et al. Tissue-Type Plasminogen Activator Crosses the Intact Blood-Brain Barrier by Low-Density Lipoprotein Receptor-Related Protein-Mediated Transcytosis Circulation, May 3, 2005; 111(17): 2241 - 2249. [Abstract] [Full Text] [PDF]

				M. Fernandez-Monreal, J. P. Lopez-Atalaya, K. Benchenane, M. Cacquevel, F. Dulin, J.-P. Le Caer, J. Rossier, A.-C. Jarrige, E. T. MacKenzie, N. Colloc'h, et al. Arginine 260 of the Amino-terminal Domain of NR1 Subunit Is Critical for Tissue-type Plasminogen Activator-mediated Enhancement of N-Methyl-D-aspartate Receptor Signaling J. Biol. Chem., December 3, 2004; 279(49): 50850 - 50856. [Abstract] [Full Text] [PDF]

				M. Yepes and D. A. Lawrence New Functions for an Old Enzyme: Nonhemostatic Roles for Tissue-Type Plasminogen Activator in the Central Nervous System Experimental Biology and Medicine, December 1, 2004; 229(11): 1097 - 1104. [Abstract] [Full Text] [PDF]

				X. Wang, K. Tsuji, S.-R. Lee, M. Ning, K. L. Furie, A. M. Buchan, and E. H. Lo Mechanisms of Hemorrhagic Transformation After Tissue Plasminogen Activator Reperfusion Therapy for Ischemic Stroke Stroke, November 1, 2004; 35(11_suppl_1): 2726 - 2730. [Abstract] [Full Text] [PDF]

				E. H. Lo, J. P. Broderick, and M. A. Moskowitz tPA and Proteolysis in the Neurovascular Unit Stroke, February 1, 2004; 35(2): 354 - 356. [Full Text] [PDF]